Sacubitril/valsartan therapy is associated with decrease of arterial elastance in stable patients with heart failure with reduced ejection fraction

Objective: Angiotensin receptor-neprilysin inhibition with LCZ696 is a novel approach for the treatment of heart failure with reduced ejection fraction (HFrEF). The aim of the study was to assess the effects of valsartan/sacubitril on parameters of ventricular-arterial coupling and left ventricular (LV) work efficiency in patients with stable HFrEF.

Source: Artery Research - November 25, 2016 Category: Cardiology Authors: Zhanna Kobalava, Svetlana Villevalde, Olga Lukina, Evgenii Tyukhmenev Source Type: research